Nektar Therapeutics (NKTR) Misses Q1 EPS by 7c, Revenues Beat

Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.78), $0.07 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $50.57 million versus the consensus estimate of $47.64 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Sinda raises $331M in IPO, reports Q2 net loss of $16.6M
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c